JP2022516088A5 - - Google Patents

Info

Publication number
JP2022516088A5
JP2022516088A5 JP2021537224A JP2021537224A JP2022516088A5 JP 2022516088 A5 JP2022516088 A5 JP 2022516088A5 JP 2021537224 A JP2021537224 A JP 2021537224A JP 2021537224 A JP2021537224 A JP 2021537224A JP 2022516088 A5 JP2022516088 A5 JP 2022516088A5
Authority
JP
Japan
Prior art keywords
cancer
protein
virus
epitope
recall
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021537224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516088A (ja
JP7641005B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/068619 external-priority patent/WO2020139978A1/en
Publication of JP2022516088A publication Critical patent/JP2022516088A/ja
Publication of JP2022516088A5 publication Critical patent/JP2022516088A5/ja
Priority to JP2024192929A priority Critical patent/JP2025023984A/ja
Application granted granted Critical
Publication of JP7641005B2 publication Critical patent/JP7641005B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021537224A 2018-12-27 2019-12-26 コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用 Active JP7641005B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024192929A JP2025023984A (ja) 2018-12-27 2024-11-01 コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785502P 2018-12-27 2018-12-27
US62/785,502 2018-12-27
PCT/US2019/068619 WO2020139978A1 (en) 2018-12-27 2019-12-26 Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024192929A Division JP2025023984A (ja) 2018-12-27 2024-11-01 コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用

Publications (3)

Publication Number Publication Date
JP2022516088A JP2022516088A (ja) 2022-02-24
JP2022516088A5 true JP2022516088A5 (enExample) 2023-01-06
JP7641005B2 JP7641005B2 (ja) 2025-03-06

Family

ID=71129893

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021537224A Active JP7641005B2 (ja) 2018-12-27 2019-12-26 コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用
JP2024192929A Pending JP2025023984A (ja) 2018-12-27 2024-11-01 コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024192929A Pending JP2025023984A (ja) 2018-12-27 2024-11-01 コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用

Country Status (10)

Country Link
US (2) US11560408B2 (enExample)
EP (1) EP3902527A4 (enExample)
JP (2) JP7641005B2 (enExample)
KR (1) KR20210110321A (enExample)
CN (1) CN113396155A (enExample)
AU (1) AU2019414934A1 (enExample)
CA (1) CA3125184A1 (enExample)
IL (1) IL284410A (enExample)
SG (1) SG11202106931PA (enExample)
WO (1) WO2020139978A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
JP2020524710A (ja) * 2017-06-23 2020-08-20 パソヴァックス エルエルシー 免疫応答の抗原特異的リダイレクターとしてのキメラウイルス様粒子およびその使用
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
AU2019414934A1 (en) * 2018-12-27 2021-06-24 Verimmune Llc Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
CA3189601A1 (en) 2020-07-24 2022-01-27 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
CA3195963A1 (en) 2020-10-19 2022-04-28 Joshua Weiyuan WANG Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer
JP2024502837A (ja) * 2021-01-14 2024-01-23 ラファエル ポール ヴィスシディ, 高病原性コロナウイルスに対する細胞傷害性t細胞免疫療法
US20240156937A1 (en) * 2021-04-23 2024-05-16 Unm Rainforest Innovations Baceriophage virus-like particles vaccines for chlamydia trachomatis infections
CN118987197B (zh) * 2024-10-24 2025-01-24 山东第二医科大学 一种自佐剂型热稳定纳米多价结核疫苗及其制备方法与应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
GB9806666D0 (en) 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
TR200102423T2 (tr) 1998-12-04 2002-02-21 Biogen, Inc. Peptid ligandları yoluyla bağlı birden fazla imünojenik bileşeni olan HBV çekirdek antijeni parçacıkları
SE514982C2 (sv) 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
CN1114690C (zh) 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
KR20050114225A (ko) 2003-03-07 2005-12-05 머크 앤드 캄파니 인코포레이티드 인플루엔자 바이러스 백신
WO2004101598A2 (en) * 2003-05-09 2004-11-25 Research Development Foundation Insertion of furin protease cleavage sites in membrane proteins and uses thereof
US7959928B2 (en) 2004-10-05 2011-06-14 Cytos Biotechnology Ag VLP-antigen conjugates and their uses as vaccines
CN101193654A (zh) * 2005-06-14 2008-06-04 赛托斯生物技术公司 抗原偶联物及其用途
US20070160628A1 (en) 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
US20070104689A1 (en) 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
MX2008007292A (es) 2005-12-08 2008-10-17 Univ Louisville Res Found Composiciones inmunoestimuladoras y metodos.
WO2008082719A2 (en) * 2006-08-30 2008-07-10 University Of Rochester Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
PT2145189E (pt) 2007-05-08 2016-06-16 Us Health Pseudovírus de papilomavírus para deteção e terapêutica de tumores
US8088392B2 (en) * 2007-06-18 2012-01-03 Yunxu Cao Capsid proteins and uses therefore
EP2217699A4 (en) * 2007-10-22 2012-11-28 Univ Rochester RESPIRATORY SYNCYTIAL VIRUS VACCINE BASED ON CHIMERIC PAPILLOMAVIRUS-SIMILAR PARTICLES OR CAPSOMERS
WO2009092113A2 (en) 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
BRPI0915076A2 (pt) 2008-06-09 2017-03-14 Bharat Biotech Int Ltd composições de vacina, composição imunogênica, método para expressão dos antígenos quiméricos de hpv-hbsag supramencionados, composição farmacêutica, método para ocasionar resposta de anticorpo protetor para composição antigênica e/ou resposta de célula t citotóxica, uso das formulações antigênicas supramencionadas.
CN107080833A (zh) 2009-04-10 2017-08-22 约翰·霍普金斯大学 作为广谱人类乳头状瘤病毒(hpv)疫苗的乳头状瘤病毒样颗粒(vlp)
CN107252489A (zh) 2009-04-13 2017-10-17 法国健康和医学研究院 Hpv颗粒及其用途
US20120052088A1 (en) 2009-04-30 2012-03-01 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2011005540A1 (en) * 2009-06-22 2011-01-13 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
US9580474B2 (en) * 2010-09-08 2017-02-28 The Johns Hopkins University Polyionic papilloma virus-like particle (VLP) vaccines
CN102153656B (zh) 2011-01-12 2014-11-19 广州市元通医药科技有限公司 一种嵌合病毒样颗粒疫苗及其制备方法
CN103561771B (zh) * 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
EA027236B1 (ru) * 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
US9771397B2 (en) 2011-12-01 2017-09-26 University Of Cape Town HPV chimaeric particle
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
US9561275B2 (en) 2012-09-14 2017-02-07 The Johns Hopkins University Compositions and methods for rendering tumor cells susceptible to CD8+ T cell-mediated killing
CA2942654A1 (en) 2013-03-15 2014-09-18 Bullet Biotechnology, Inc. Specific multivalent virus-like particle vaccines and uses thereof
EP3046583B1 (en) 2013-09-18 2019-02-13 Aura Biosciences, Inc. Virus-like particle conjugates for treatment of tumors
ES2738582T3 (es) * 2014-02-14 2020-01-23 Immune Design Corp Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica
WO2015196112A1 (en) 2014-06-19 2015-12-23 The Regents Of The University Of Colorado, A Body Corporate Human papilloma virus constructs
EP3215520B1 (en) * 2014-11-07 2022-01-05 Case Western Reserve University Cancer immunotherapy using virus particles
WO2016112921A1 (en) 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display
ES2727552T3 (es) 2015-02-18 2019-10-17 Hoffmann La Roche Inmunoconjugados para la inducción específica de la citotoxicidad de los linfocitos T frente a una célula diana
US11213577B2 (en) 2015-04-28 2022-01-04 Albert Einstein College Of Medicine, Inc. Treatment of cancer using recall antigens delivered by attenuated bacteria
WO2017020570A1 (en) 2015-08-06 2017-02-09 Medigen Biotechnology Corp. Virus-like particle vaccines
CA2996762A1 (en) * 2015-08-31 2017-03-09 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
WO2017075615A1 (en) 2015-10-29 2017-05-04 Bullet Biotechnology, Inc. Virus-like particle intermediates, agents attached thereto, methods for making and uses thereof
EP3368068B1 (en) 2015-10-30 2020-11-18 University of Copenhagen Virus like particle with efficient epitope display
JP2018532801A (ja) 2015-10-30 2018-11-08 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 標的化がん療法
WO2017075399A1 (en) * 2015-10-30 2017-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Targeted cancer therapy
EP3370755B1 (en) 2015-11-06 2021-09-29 Regents of the University of Minnesota Activation of resident memory t cells for cancer immunotherapy
FI3377103T4 (fi) 2015-11-19 2025-04-16 Revitope Limited Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
WO2017112830A1 (en) 2015-12-21 2017-06-29 La Jolla Institute For Allergy And Immunology Leveraging immune memory from common childhood vaccines to fight disease
WO2017112797A1 (en) 2015-12-22 2017-06-29 Thomas Jefferson University Intra-lesional cmv-based cancer vaccines
WO2017177204A1 (en) 2016-04-09 2017-10-12 La Jolla Institute For Allergy And Immunology Leveraging immune memory from common childhood vaccines to fight disease
WO2018106972A1 (en) * 2016-12-07 2018-06-14 La Jolla Institute For Allergy And Immunology Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
US11197890B2 (en) 2016-12-12 2021-12-14 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Methods of treating cancer, infectious disease, and autoimmune disease using CXC chemokines
JP2020524710A (ja) 2017-06-23 2020-08-20 パソヴァックス エルエルシー 免疫応答の抗原特異的リダイレクターとしてのキメラウイルス様粒子およびその使用
EP3661550A4 (en) 2017-08-03 2021-08-04 Regents of the University of Minnesota ACTIVATION OF LYMPHOCYTES T MEMORY RESIDENTS FOR THE TREATMENT OF CANCER
KR20250044945A (ko) 2017-11-06 2025-04-01 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 기존의 미생물 면역을 활용한 암 치료
WO2020017962A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.
AU2019414934A1 (en) * 2018-12-27 2021-06-24 Verimmune Llc Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
AU2020248407C1 (en) 2019-03-26 2025-12-04 Aura Biosciences, Inc. Human papillomavirus nanoparticle formulations

Similar Documents

Publication Publication Date Title
JP2022516088A5 (enExample)
JP7641005B2 (ja) コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用
JP2022166110A (ja) アデノウイルスコートタンパク質由来送達賦形剤
ES2213754T3 (es) Particulas quimericas de tipo papilomavirus.
JP2016533332A5 (enExample)
JP2016526374A5 (enExample)
JP2012501347A5 (enExample)
JP2007512842A5 (enExample)
MXPA05009289A (es) Conjugados de particulas tipo virus del analogo del peptido melan-a.
Lei et al. Genetic engineering strategies for construction of multivalent chimeric VLPs vaccines
EP2425848A3 (en) Influenza immunogen and vaccine
KR102797824B1 (ko) 키메라 바이러스-유사 입자 및 면역 반응의 항원-특이적 재지향자로서의 이의 용도
JP2023501979A (ja) 改変カプシドタンパク質を備えるウイルス
JP2013517773A5 (enExample)
JP2020524710A5 (enExample)
JP2009501001A5 (enExample)
JP2011530524A5 (enExample)
JP2010508857A5 (enExample)
JP2019502404A5 (enExample)
ES2275350T3 (es) Sistema de administracion de proteinas usando particulas de tipo virus de papilomavirus humano.
TW201546087A (zh) 經官能化以供癌症靶向之化學活化的奈米蛋白殼體
Saba et al. Platform technologies based on virus-like particles (VLPs) for infectious diseases
Venkataraman et al. Biomedical applications of viral nanoparticles in vaccine therapy
Truong et al. Self-adjuvanting peptide vaccines against cervical cancer
Curiel Strategies to alter the tropism of adenoviral vectors via genetic capsid modification